Best Information Technology Companies To Watch For 2015

Best Information Technology Companies To Watch For 2015: Lexicon Pharmaceuticals Inc.(LXRX)

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of drug candidates for the treatment of various human diseases. The company utilizes gene knockout technologies and an integrated platform of medical technologies to systematically study the physiological and behavioral functions of approximately 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as drug targets. Its portfolio of orally-delivered small molecule compounds that have completed or are presently conducting phase 2 clinical trails includes LX4211 for the treatment of type 2 diabetes; LX1031 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX1032 for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of rheumatoid arthritis and other autoimmune diseases. The company also develops LX1033, an orally-delivered small molecule compound that is in phase 1 clinical trails for the treatment of irritable bowel syndrome and other gastrointestinal disorders. In addition, it develops three orally-delivered small molecule compounds in preclinical development stage that include LX7101 for treatment of glaucoma; LX5061 for the treatment of osteoporosis; and LX2311 for the treatment of autoimmune diseases. Further, the company has small molecule compounds from various additional drug discovery programs in various stages of preclinical research. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. The company also has a series of agreements with Symphony Icon, Inc. for the financing of clinical development programs; and an alliance with Nuevolution A/S to access Nuevoluti! on?s Chemetics chemistry technology. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.

Advisors' Opinion:

• [By Lauren Pollock]

  Among the companies with shares expected to actively trade in Tuesday’s session are OncoMed Pharmaceuticals Inc.(OMED), Lexicon Pharmaceuticals Inc.(LXRX) and Krispy Kreme Doughnuts Inc.(KKD)

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech company Lexicon Pharmaceuticals (NASDAQ: LXRX  ) has received a distressing two-star ranking.

• [By Lauren Pollock]

  Lexicon Pharmaceuticals Inc.(LXRX) said a pilot study of a treatment for ulcerative colitis showed certain clinical benefits, but the results lacked other findings that would indicate a large enough impact to move ahead on developing the treatment for this particular use. Shares dropped.

• [By Bryan Murphy]

  Over the past few weeks, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) and Decision Diagnostics Corp. (OTCBB:DECN) have dominated the diabetes diagnostics and diabetes treatment landscape. Shares of LXRX jumped 20% on Tuesday following news that one of the key drugs in its pipeline showed more than enough efficacy in its clinical trials. DECN shares are up more than 250% on the heels of an almost-assured victory in its patent lawsuit against industry giant Johnson & Johnson (NYSE:JNJ). Anyone looking for a new trade in the diabetes diagnostics space, however, may want to look past overbought Lexicon Pharmaceuticals and Decision Diagnostics at this point, and instead turn their attention to newly-budding Neurometrix Inc. (NASDAQ:NURO).

source from Top Stocks For 2015:http://www.topstocksblog.com/best-information-technology-companies-to-watch-for-2015.html